Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptorum Group Ltd Cl A (NQ: APM )

2.165 -0.295 (-11.99%)
Streaming Delayed Price Updated: 3:57 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptorum Group Ltd Cl A

< Previous 1 2 3 4 5 6 Next >
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S.
From Aptorum Group Limited
Via Business Wire
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients
The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is... 
Via Benzinga
Exposures Product Safety
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate
Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life... 
Via Benzinga
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
From Aptorum Group Limited
Via Business Wire
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Aptorum Group Limited
Via Business Wire
Aptorum Group CEO Subscribed Shares In The Company
From Aptorum Group Limited
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's... 
Via Benzinga
58 Biggest Movers From Friday
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indicating equipment billings increased 50% in April compared to the prior year's... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
Via Benzinga
Exposures Product Safety
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Monday's Mid-Day Session
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive... 
Via Benzinga
Exposures Product Safety
Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study
Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4... 
Via Benzinga
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference
From Aptorum Group Limited
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Conformis (NASDAQ:CFMS) stock moved upwards by 29.53% to $1.09 during Monday's pre-market session. The company's market cap stands at $198.8 million. As... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Aptorum Group Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.